SAN FRANCISCO, CA--(Marketwire - June 22, 2010) - AmStem Corporation
), a world leader in stem cell research using stem cells collected from the umbilical cord immediately after birth, announced today the launch of a new consumer-based study of its flagship cosmeceutical product SteMixx™.
AmStem President David Stark said, "This consumer-based study of SteMixx™ is a prelude to the first Institutional Review Board ("IRB") approved clinical trial in the U.S. beginning sometime next month. The IRB is responsible for the protection of participants in the trial and for evaluating the scientific validity of the protocol. Most cosmetic companies don't take on the added expense, rigor and responsibility of protecting participants in their studies, but AmStem is committed to the highest ethical and professional standards in the field."
"In fact, the protocol we are employing is much more rigorous than most consumer-based cosmetic studies. It involves strict inclusion and exclusion criteria. Participants must refrain from using other facial cosmetics for one month. So far response from those wishing to participate in the free trial study has been enthusiastic," Stark said.
Participants in the consumer-based study will use SteMixx™ exclusively for a month and provide subjective data on efficacy, product characteristics and satisfaction. The data will be used to support AmStem's ongoing marketing campaigns for the full launch of SteMixx™ sales in high-end e-commerce, retail and wholesale markets next quarter. As of this release, a few spots still remain open for enrollment. See the study web page (http://amsteminc.com/index.php?option=com_content&view=article&id=80) for details.
SteMixx™, along with an extensive line of cosmeceutical and hair restoration products, was developed by Dr. Han Hoon, CEO of Histostem, Ltd., in Seoul, Korea. Histostem is a 90% owned subsidiary of AmStem Corporation. Histostem operates one of the largest cord blood banks in the world with over 80,000 units stored for personal and unrelated transplant uses.
SteMixx™ has been approved by the Korean FDA as a "functional cream" for the treatment of facial skin disfiguration associated with signs of aging such as wrinkles. AmStem's professional studies are for the purpose of validating these claims, which have not yet been reviewed by the U.S. FDA.
About AmStem Inc.
AmStem Inc. is a corporation registered in the State of Nevada with offices in San Francisco, California and Seoul, Korea. The company is a world leader in the area of stem cell research using stem cells derived from the umbilical cord immediately after birth. The company has 19 U.S. and international patents related to stem cell processing, application and clinical treatments. AmStem owns one of the largest cord blood stem cell banks in the world with more than 80,000 cord blood units stored in Korea. The facility in Korea is highly accredited including Korean FDA approval (KFDA). The units of cord blood are processed and stored by the company for use in unrelated transplant for personal storage and for use in the family setting for transplant and regenerative medicine. The company is developing a line of cosmeceuticals based upon its proprietary stem cell technology and sourcing its own materials from its expansive operation in Korea. The company has treated more than 800 people in clinical trials for purposes of developing its patent portfolio.
An investment profile on AmStem may be found at http://www.hawkassociates.com/profile/amst.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.
Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for AmStem Corporation may be forward-looking statements that involve a number of risks and uncertainties. For these statements, we claim the protection of the safe harbor for forward-looking statement contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, successfully complete clinical trials, our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capability or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in the press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statement to reflect events or circumstances that occur after the date hereof.